Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort
| Image |  |
|---|---|
| Description | scientific article published on 01 December 2019 |
| Author/s |
author: Antonio Calles Domenico Galetta |
| Publication date | December 1, 2019 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |